All In Biotech

Drug Trial Radar · NCT00050375

Clinical Trial for Ovarian Cancer (OvaRex®)

A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin

Last checked: Nov 19, 2026Latest source record: Dec 18, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

354

Actual

Start

Dec 2002

Primary completion

Not stated

Study completion Dec 2007

Sponsor

Lead sponsor
Unither PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 6, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Conditions

  • Ovarian Cancer

Interventions

  • oregovomabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

62 sites in 1 country. Site status is shown where the registry gives one.

  • Comprehensive Cancer Institute

    Huntsville, Alabama

  • Western Regional Community Clinical Oncology Program

    Phoenix, Arizona

  • Little Rock Hematology Oncology Assoc.

    Little Rock, Arkansas

  • St. Jude Medical Center

    Fullerton, California

  • Wilshire Oncology Medical Group

    La Verne, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA School of Medicine

    Los Angeles, California

  • Gynecologic Oncology Associates

    Newport Beach, California

  • University of California, Irvine

    Orange, California

  • Sharp Memorial Hospital

    San Diego, California

  • Stanford University

    Stanford, California

  • Rocky Mountain Cancer Center-Midtown

    Denver, Colorado

  • University of Connecticut Cancer Center

    Farmington, Connecticut

  • Northwestern Connecticut Oncology Hematology Associates, LLP

    Torrington, Connecticut

  • Florida Gynecologic Oncology

    Fort Myers, Florida

  • Florida Hospital Cancer Institute

    Orlando, Florida

  • Pensacola Research Consultants

    Pensacola, Florida

  • H. Lee Moffitt Cancer Center and Research

    Tampa, Florida

  • Medical College of Georgia

    Augusta, Georgia

  • The University of Chicago Hospitals

    Chicago, Illinois

  • St. Vincent Gynecologic Oncology

    Indianapolis, Indiana

  • Michiana Hematology Oncology PC

    South Bend, Indiana

  • Brown Cancer Center

    Louisville, Kentucky

  • Louisville Oncology

    Louisville, Kentucky

  • Lake Charles Medical Surgical Clinic

    Lake Charles, Louisiana

  • Hematology and Oncology Specialists

    New Orleans, Louisiana

  • The Harry and Jeanette Weinberg Cancer Institute

    Baltimore, Maryland

  • New England Medical Center

    Boston, Massachusetts

  • Women's Specialty Center

    Jackson, Mississippi

  • Ellis Fischel Cancer Center

    Columbia, Missouri

  • Jersey Shore Medical Center

    Neptune City, New Jersey

  • North Shore University Hospital

    Manhasset, New York

  • St. Vincent's Comprehensive Cancer Center

    New York, New York

  • Nyack Hospital

    Nyack, New York

  • SUNY-HSC Syracuse, Crouse Hospital

    Syracuse, New York

  • Blumenthal Cancer Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University Hospital - Health Systems

    Cleveland, Ohio

  • GYN Oncology and Pelvic Surgery Associates

    Columbus, Ohio

  • ProMedica Health Systems

    Toledo, Ohio

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.